



Anoro Ellipta® (umeclidinium/vilanterol) – First-time authorized brand alternative

- On April 14, 2025, [Prasco launched](#) an authorized brand alternative of GSK's [Anoro Ellipta \(umeclidinium/vilanterol\)](#) inhalation.
- Anoro Ellipta is approved for the maintenance treatment of patients with chronic obstructive pulmonary disease.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.